Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) Gross Margin (2022 - 2025)

Historic Gross Margin for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to 73.25%.

  • Indivior Pharmaceuticals' Gross Margin fell 52500.0% to 73.25% in Q3 2025 from the same period last year, while for Sep 2025 it was 80.42%, marking a year-over-year increase of 2900.0%. This contributed to the annual value of 80.56% for FY2024, which is 35200.0% down from last year.
  • As of Q3 2025, Indivior Pharmaceuticals' Gross Margin stood at 73.25%, which was down 52500.0% from 82.78% recorded in Q2 2025.
  • Over the past 5 years, Indivior Pharmaceuticals' Gross Margin peaked at 86.62% during Q1 2024, and registered a low of 73.25% during Q3 2025.
  • Over the past 4 years, Indivior Pharmaceuticals' median Gross Margin value was 82.77% (recorded in 2022), while the average stood at 81.46%.
  • As far as peak fluctuations go, Indivior Pharmaceuticals' Gross Margin tumbled by -83100bps in 2024, and later soared by 92000bps in 2025.
  • Over the past 4 years, Indivior Pharmaceuticals' Gross Margin (Quarter) stood at 82.16% in 2022, then rose by 0bps to 82.25% in 2023, then grew by 1bps to 83.22% in 2024, then dropped by -12bps to 73.25% in 2025.
  • Its Gross Margin was 73.25% in Q3 2025, compared to 82.78% in Q2 2025 and 83.08% in Q1 2025.